The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2SARS-CoV-2에 결합하는 수렴형 IGHV3-53/3-66 항체에 대한 CDR1 체세포 과돌연변이의 두드러진 역할Article Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome Analysis antibodies antibody antibody affinity binding binding affinity Cdr1 contributed Coronavirus-2 COVID-19 Frequency functional germline gene Humoral immunity IGHV3-53/3-66 knowledge mAb mAbs monoclonal monoclonal antibody Mutation other coronaviruses SARS-CoV-2 somatic hypermutation. somatic hypermutations Treatment [DOI] 10.1080/22221751.2022.2063074 PMC 바로가기 [Article Type] Article
Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivitySARS-CoV-2 변이체 B.1.617 분석: 숙주 친화성, 단백질 분해 활성화, 세포-세포 융합 및 중화 민감도Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] activity Adenovirus adenovirus vaccine Amino acid B.1.617 caused cell-cell fusion cell–cell fusion cells Characteristics Convalescent patients COVID-19 pandemic D614G variant Delta escaped furin host tropism human cells immunized inactivated Inactivated vaccine India Infection Infectivity L452R mAbs Mutation mutations neutralization neutralization activities neutralization activity neutralization. pathogenicity proteolytic activation pseudotyped pseudotyped virus Receptor binding domain reduced SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sensitivity sera T478K Transmissibility transmitted variant variants viruses volunteers [DOI] 10.1080/22221751.2022.2054369 PMC 바로가기 [Article Type] Article
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodiesArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, [키워드] antibody Antibody structure caused consequence COVID-19 pandemic Critical cryo-EM develop effective effort epitope Host Infection mAbs mechanism molecular monoclonal antibody Neutralizing neutralizing antibody neutralizing mechanism pan-coronavirus vaccine. provide public health SARS-CoV-2 SARS-CoV-2 antibody Scientific community the spike protein Vaccine Vaccines [DOI] 10.1080/22221751.2022.2125348 PMC 바로가기
Expediting the chromatographic analysis of COVID-19 antibody therapeutics with ultra-short columns, retention modeling and automated method developmentArticle Published on 2022-11-302022-11-15 Journal: Journal of pharmaceutical and biomedical analysis [Category] SARS, 진단, [키워드] Analysis automated Automation Casirivimab collected complementary COVID-19 COVID-19 antibody COVID-19 pandemic drug candidate Effect Emergency use authorization EUA experimental work feasible help hospitalized patient Imdevimab infected with SARS-CoV-2 mAb mAbs monoclonal antibody passive immunity performed Protein required retention Retention modeling SEC submission turnaround times Ultra-short column. Vaccines [DOI] 10.1016/j.jpba.2022.115039 PMC 바로가기
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domainSARS-CoV-2 S2 도메인에 대한 항체의 결합 및 중화 능력Article Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody B.1.1.7 B.1.351 B.1.617.2 B.1.621 binding binding activity carried conserved convalescent patient coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 determined by domain ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence Immune escape immune protection mAb mAbs MERS MERS-CoV Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus molecular monoclonal antibodies monoclonal antibody N Terminal N terminal domain NAbs Neutralization assay neutralization assay. Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody NTD P.1 Protein pseudo-virus RBD Receptor binding domain reported Research respiratory Result S protein S proteins S2 protein S2 subunit SARS-CoV SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 S SARS-CoV-2 S2 SARS-CoV-2 WT Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly specific antibodies subunit target targets terminal Vaccine design variant variants wild-type [DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatientsArticle Published on 2022-11-072022-11-16 Journal: BMC Infectious Diseases [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval adjusted odds ratio Administered age Characteristics clinical trial Comorbidity COVID-19 COVID-19 outpatient death defined died early symptomatic COVID-19 effective Electronic health record health system Hospitalization Hospitalized immunocompromised status lack mAb mAbs Male sex Mild monoclonal antibodies monoclonal antibody monoclonal antibody treatment Mortality mortality data multicenter Neutralizing obesity Observational cohort study occurred pandemic Patient patients patients with COVID-19 positive Primary outcome real-world data reducing SARS-CoV-2 SARS-CoV-2 test SARS-CoV-2 vaccination SARS-CoV-2. Treatment Vaccine variants while [DOI] 10.1186/s12879-022-07819-z PMC 바로가기
An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunizationArticle Published on 2022-11-052022-11-15 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition Antigen antigens applied approach approaches binding affinity circumvent complementary COVID-19 COVID-19 pandemic Delta Diseases evaluated functional fusion strategy generate immunization introduced lack Lipid Lipid nanoparticle (LNP) LNP mAb mAbs Membrane proteins methodology mice Modified mRNA monoclonal antibodies monoclonal antibody neutralize Neutralizing Neutralizing activity posttranslational modification Prophylactic Protein RBD Receptor binding domain SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 spike SARS-CoV-2 virus SARS-CoV-2. serum serum antibody several variants therapeutic drug Treatment Vaccines variants [DOI] 10.1016/j.ijpharm.2022.122256 PMC 바로가기
Monoclonal antibody therapies against SARS-CoV-2Article Published on 2022-11-012022-11-15 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibody authorisation B.1.1.529 baseline clinical trial COVID-19 pandemic Immune escape intrinsic limitation mAb mAbs monoclonal antibody therapy outcome outcomes pandemic SARS-CoV-2 the spike protein therapeutic agents treatment strategy variant [DOI] 10.1016/S1473-3099(22)00311-5 PMC 바로가기
Potential of antibody pair targeting conserved antigenic sites in diagnosis of SARS-CoV-2 variants infectionArticle Published on 2022-11-012022-11-15 Journal: Journal of virological methods [Category] SARS, 변종, 진단, 치료기술, 치료제, [키워드] antibody Antibody pair Antigen antigenic site antigenic sites binding domain candidate caused clinical samples Clusters complex conformational conserved Coronavirus disease 2019 COVID-19 COVID-19 pandemic demonstrated determine develop diagnosis of SARS-CoV-2 diagnostic early diagnosis ELISA Infection mAb mAbs monoclonal antibody pandemic Potential pseudovirus RBD RBD-specific mAbs recognizing residue SARS-CoV SARS-CoV S protein SARS-CoV-2 SARS-CoV-2 receptor SARS-CoV-2 S protein SARS-CoV-2 variant selected Sensitivity and specificity spike Spike antigen. Spike protein substitutions Treatment variant VOCs [DOI] 10.1016/j.jviromet.2022.114597 PMC 바로가기
Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective studyArticle Published on 2022-10-202022-11-15 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] adverse events Algorithm antibody Antiviral antiviral drug antivirals approved benefit Calabria case sery clinical clinical evolution Combination combination therapy combined use coronavirus disease COVID-19 COVID-19 progression drug Early therapies early treatment effective Effectiveness Efficacy escape mutant group Health services hospital Hospital admission hospitalisation Hospitalized hypothesised Immunocompromised immunocompromised individuals implication increase in lesson mAb mAbs malignancy monoclonal antibodies monoclonal antibody monotherapy Patient patients patients treated progression provided receive reduce reported Retrospective study SARS-CoV-2 SARS-CoV-2 genome Support symptom onset Territorial health services. Therapies therapy treated treated patient Treatment [DOI] 10.1186/s12879-022-07774-9 PMC 바로가기